Omnio is a pioneer in pro-inflammatory drug development, providing a protein found in plasma as a solution to treat hard-to-heal wounds, periodontitis and other indications caused by defective inflammatory response. The company has outlicensed two indications to a Candian biopharma company based on previous pre-clinical data, and Omnio is now developing pre-clincal data for additional indications. These indications may be out-licensed based on pre-clinical data; or retained through first phases of clinical trials.
VISIT SITEOmnio
